Search clinical trials for: metronomic cyclophosphamide

Total 3698 results

John Reneau

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/Lymphoma

United States
Institut Bergonié
PharmaMar

Completed

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (TARMIC)

Soft-tissue Sarcomas

France
Zhi-Hong Liu, M.D.

Terminated

The Clinical Efficacy of DFPP in Patients With AAGN

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

China
Tufts Medical Center

Withdrawn

Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer

Breast Cancer
Cooperative Study Group A for Hematology

Completed

Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT (CyFluCyATG)

Bone Marrow Failure Syndromes

Korea, Republic of
Institut Bergonié
Merck Sharp & Dohme LLC; National Cancer Institute, France; Transgene; Fondation...

Recruiting

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX)

Breast Cancer | Soft-tissue Sarcoma | Solid Tumors

France
Tao OUYANG

Completed

Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Progressive Disease | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Minimal Residual Disease | Recurrent Chronic Lymphocytic Leukemia | CD19 Positive | CD22...

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

Acute Myeloid Leukemia | Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Secondary Myelofibrosis

United States
Guangdong Provincial People's Hospital

Unknown

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Breast Cancer

China
Alentis Therapeutics AG

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02) (RENAL-F02)

Glomerulonephritis Rapidly Progressive

Czechia, Spain, Germany, Denmark, Italy, United Kingdom, France, Switzerland, Sweden, Turkey
Wuhan Union Hospital, China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Duke University
United States Department of Defense

Terminated

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Early-Stage Breast Cancer

United States
Fudan University
Chinese Anti-Cancer Association

Completed

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Primary Breast Cancer

China
Jonsson Comprehensive Cancer Center

Recruiting

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Progressive Disease | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Completed

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Recurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid Liposarcoma

United States
RenJi Hospital
Westlake Therapeutics

Not yet recruiting

A Exploratory Trial of WTX221 in Refractory Gout Patients

Gout Tophus
All India Institute of Medical Sciences, New Delhi

Not yet recruiting

Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis

Tuberculosis | Tubercular Meningitis | Arachnoiditis; Tuberculous (Etiology)
National Cancer Centre, Singapore

Completed

Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas

Sarcoma

Singapore
Johns Hopkins University

Completed

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

Pemphigus

United States
The Christie NHS Foundation Trust
Merck Sharp & Dohme LLC; University of Manchester; Liverpool Clinical Trials...

Recruiting

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (CAPER)

Metastatic Renal Cell Carcinoma

United Kingdom
Fred Hutchinson Cancer Center
Mustang Bio

Active, not recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
First Affiliated Hospital of Harbin Medical University

Unknown

Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy

Microbiota

China
Capital Research Institute of Pediatrics

Unknown

Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome

Wiskott-Aldrich Syndrome
Cambridge University Hospitals NHS Foundation Trust

Completed

Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides

Wegener's Granulomatosis | Microscopic Polyangiitis | ANCA Associated Systemic Vasculitis
M.D. Anderson Cancer Center

Active, not recruiting

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Baylor Research Institute

Terminated

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Malignant Melanoma Stage IV

United States
ChemoCentryx

Completed

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

ANCA-associated Vasculitis

United States, Canada
The Netherlands Cancer Institute

Active, not recruiting

Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer (neo-TN)

Breast Cancer

Netherlands
Seoul National University Hospital
National Institute of Food and Drug Safety Evaluation (Republic of Korea)

Not yet recruiting

Pharmacokinetic Study of Post-transplant Cyclophosphamide in Pediatric Patients

Hematopoietic Stem Cell Transplantation
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma

Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms | Multiple Myeloma and Malignant Plasma Cell Neoplasms

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Brain Neoplasm | Refractory Brain Neoplasm

United States
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
European Organisation for Research and Treatment...
Pfizer; ETOP IBCSG Partners Foundation; UNICANCER; Breast International Group; SOLTI... and other collaborators

Active, not recruiting

Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

Breast Cancer Stage II | Breast Cancer Stage III

Spain, France, Italy, Belgium, Jordan, Poland, Germany, United Kingdom, Portugal
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Aplastic Anemia | Paroxysmal Hemoglobinuria, Nocturnal

United States
Huazhong University of Science and Technology

Completed

Low Dose Cyclophosphamide Treats Genital Warts

Genital Wart

China
Johns Hopkins University

Completed

Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

Autoimmune Diseases | Purpura, Thrombocytopenic | Anemia, Hemolytic, Autoimmune | Felty Syndrome

United States
University Hospital, Basel, Switzerland
University Hospital, Geneva; University Hospital, Zürich

Completed

Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT

Myeloid Leukemia | Precursor Myeloid Neoplasms | Lymphoid Neoplasms

Switzerland
Peking University People's Hospital

Completed

Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

Hematopoietic Stem Cell Transplantation

China
Baylor College of Medicine
Pediatric Brain Tumor Consortium

Completed

Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) (KTN10010)

Solid Tumors

United States
Rambam Health Care Campus

Completed

High Dose CHOP in Lymphoma

Non-Hodgkin's Lymphoma

Israel
Shandong Cancer Hospital and Institute

Unknown

Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (BCSMANC)

Breast Cancer

China
Masonic Cancer Center, University of Minnesota

Completed

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Leukemia

United States
Johns Hopkins University

Completed

High Dose Cyclophosphamide for Treatment of Scleroderma

Scleroderma
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
Crystal Mackall, MD
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | CD19 Positive

United States

Search clinical trials for: metronomic cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations